Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01109537 · ClinicalTrials.gov registry record
Altered Brain GABA and Glutamate in Restless Legs Syndrome
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 75
- Enrollment target
NCT01109537: Completed study, sponsored by Brigham and Women's Hospital.
NCT01109537 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 75 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01109537 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
Study Summary
The purpose of the study is to understand the brain chemistry of people with Restless Legs Syndrome (RLS). The primary hypothesis is that patients with RLS will have reduced GABA levels in their Thalamus and elevated Glutamate levels in their Anterior Cingulate Cortex. The study will use MRS imaging to examine the regional levels of these neurochemicals, GABA and Glutamate, in the brain.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2010-04 |
| Est. Completion | 2014-05 |
What the finished NCT01109537 record still lists
NCT01109537 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 75 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01109537 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01109537 about?
NCT01109537 is a clinical study titled "Altered Brain GABA and Glutamate in Restless Legs Syndrome". The purpose of the study is to understand the brain chemistry of people with Restless Legs Syndrome (RLS). The primary hypothesis is that patients with RLS will have reduced GABA levels in their Thalamus and elevated Glutamate levels in their Anterior Cingulate Cortex. The study will use MRS imaging...
What is the current status of trial NCT01109537?
This trial is currently completed. The enrollment target is 75 participants. The study started on 2010-04. Estimated completion is 2014-05.
Who is sponsoring clinical trial NCT01109537?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia